Comparative Pharmacology
Head-to-head clinical analysis: BETAMETHASONE VALERATE versus CELESTONE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: BETAMETHASONE VALERATE versus CELESTONE.
BETAMETHASONE VALERATE vs CELESTONE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Betamethasone valerate is a corticosteroid that binds to the glucocorticoid receptor, leading to increased synthesis of lipocortin, which inhibits phospholipase A2 and reduces arachidonic acid release, thereby decreasing prostaglandin and leukotriene production. It also suppresses cytokine expression and inflammatory cell migration.
Celestone (betamethasone) is a corticosteroid that binds to the glucocorticoid receptor, modulating gene expression to produce anti-inflammatory, immunosuppressive, and antiproliferative effects. It inhibits phospholipase A2, reducing prostaglandin and leukotriene synthesis, and suppresses cytokine production.
Apply a thin film to affected area twice daily. Maximum 15 g/day for 2 weeks.
Betamethasone (Celestone) 0.6-7.2 mg/day orally in divided doses; 0.6-9.0 mg/day IM or IV as betamethasone sodium phosphate; dose adjusted based on severity.
None Documented
None Documented
Terminal elimination half-life is approximately 36–54 hours for the parent drug after topical application; systemic absorption is low. For oral or IV administration, the half-life is about 3–5 hours, but clinical effects persist longer due to receptor-mediated mechanisms.
Terminal elimination half-life of betamethasone (active component) is 36-54 hours (mean ~44 hours) in adults, providing sustained adrenal suppression.
Renal (primarily as metabolites, unchanged drug <5%). Biliary/fecal elimination accounts for a minor fraction. Essentially no significant renal excretion of active drug.
Renal: 75-90% as metabolites (glucuronides and sulfates) and <5% unchanged; biliary/fecal: 10-25%.
Category D/X
Category C
Corticosteroid
Corticosteroid